Omalizumab is used to treat moderate to severe allergic asthma not controlled by inhaled corticosteroids. It’s also approved for chronic spontaneous urticaria (CSU) and nasal polyps in certain patients. It works by binding to IgE, reducing allergic inflammation. It is grouped under the following drug class(es): Immunosuppressants and Monoclonal antibodies. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Xolair PFS, Anti-IgE Monoclonal Antibody E25 and Olizumab. Its PubChem SID is 481101771.
Omalizumab
| CAS No | 242138-07-4 |
|---|---|
| Molecular Formula | C₆₅₃₄H₁₀₀₄₆N₁₇₁₄O₂₀₃₂S₃₈ |
| Molecular Weight | 149 kDa |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Omalizumab is used to treat moderate to severe allergic asthma not controlled by inhaled corticosteroids. It’s also approved for chronic spontaneous urticaria (CSU) and nasal polyps in certain patients.
The listed CAS number is 242138-07-4.
The listed molecular formula is C₆₅₃₄H₁₀₀₄₆N₁₇₁₄O₂₀₃₂S₃₈.
The listed molecular weight is 149 kDa.
The source lists Xolair PFS, Anti-IgE Monoclonal Antibody E25 and Olizumab.
Its therapeutic use is listed as anti-asthmatic agents.